In this installment of Chief Insights in Oncology, John M. Burke, MD, co-editor in chief of Targeted Therapies in Oncology, discusses his column from the September II 2025 issue.

About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely ...

Leukemia is a blood cancer that disrupts normal cell production, leading to infection risk, anemia and bleeding, and requiring tailored treatments.

(WASHINGTON, June 21, 2024) – Patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas (NHLs) who received frequent tests for immunoglobulin G (IgG) were less likely to experience ...

A new bone marrow test can help doctors predict risk of leukemia relapse The test might double survival rates by predicting a relapse up to three months earlier than standard care The test looks for ...

Patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas (NHLs) who received frequent tests for immunoglobulin G (IgG) were less likely to experience severe infections compared with ...

Open-Source Hybrid Large Language Model Integrated System for Extraction of Breast Cancer Treatment Pathway From Free-Text Clinical Notes The diagnosis of chronic lymphocytic leukemia (CLL) is often ...

Chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL) are types of blood cancer. They develop in types of white blood cells called B cells or T cells, or the precursors to these cells.

MONDAY, May 5, 2025 (HealthDay News) — Testing positive for leukemia actually saved the life of 51-year-old Jan Leahy, a business process owner from Wimbledon, England. Leahy benefitted from a ...